NCT04059679View on ClinicalTrials.gov

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

August 31, 2021

Conditions
Coronary Artery DiseasePeripheral Artery Disease
Interventions
DRUG

Rivaroxaban 2.5 Mg Oral Tablet

EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)

DRUG

Aspirin 81 mg

EC aspirin 81 mg qd

Trial Locations (1)

21215

RECRUITING

Sinai Hospital of Baltimore, Baltimore

Sponsors

Lead Sponsor

LifeBridge Health
All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

LifeBridge Health

OTHER

NCT04059679 - Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy | Biotech Hunter | Biotech Hunter